Research of the HER2 gene mutations may determinate the patients with relatively higher risk from the entire HER2‐negative breast cancer patients and open up a new pointcut to treat HER2‐negative breast cancer precisely. This evidence concerns the gene ERBB2 and breast carcinoma.